For example, a Phase II Trial of Ipilimumab (Anti-CTLA4) and Nivolumab (Anti-PD-1) conducted in unresectable or metastatic metaplastic BC, part of the patients in this trial have luminal tumors2,54. Here, CTLA4 is linked to breast cancer.